Sharesmagazine
 Home   Log In   Register   Our Services   My Account   Contact   Help 
 Stockwatch   Level 2   Portfolio   Charts   Share Price   Awards   Market Scan   Videos   Broker Notes   Director Deals   Traders' Room 
 Funds   Trades   Terminal   Alerts   Heatmaps   News   Indices   Forward Diary   Forex Prices   Shares Magazine   Investors' Room 
 CFDs   Shares   SIPPs   ISAs   Forex   ETFs   Comparison Tables   Spread Betting 
You are NOT currently logged in
Register now or login to post to this thread.
  • Page:
  • 1
  • 2
  • 3

gibby - 14 Feb 2011 12:37

Dr Satu Vainikka, CEO commented:

"I am delighted that we are now launching our Chlamydia self-testing product into the UK and Irish markets. With Chlamydia being diagnosed as the fastest growing sexually transmitted disease at the moment, our self-testing pack, as an affordable, easy -to-use and rapid indicator of the presence or absence of the Chlamydia bacterium has the potential to become a first line test against Chlamydia. With the disease having the potential to affect fertility in both sexes, I particularly urge young people looking to start a family to test themselves early. Early detection will mean early intervention and thinking that there is not a problem is just not thinking."

Broker Hybridan was positive about the launch, stating that ValiRx remains far from fully valued at these levels.

We like the model of product on the market generating revenues in the test kits and the more blue sky upside that its proprietary drug development programmes provide in the technology platform, said Hybridan.

Last month, ValiRx completed the sale of its Belgian diagnostic development business, ValiBIO SA, to Singapore Volition Pte Ltd, having received all the funds it was due.

ValiRx continues to retain its significant shareholding in Volition and in the future upside value and growth of the business and integration between the companies is progressing well

http://www.proactiveinvestors.co.uk/companies/news/25504/valirx-aim-stock-out-of-the-doldrums-25504.html


skyhigh - 22 Jan 2013 11:50 - 52 of 55

Val stirring at long last!

DirectorsTalk.com – Investment analyst covering ValiRx Plc advises that the company will outperform the market.

"The one analyst offering a 12 month price target expects ValiRx Plc share price to rise to 2.16 in the next year from the last price of 0.48."

http://markets.ft.com/research/Markets/Tearsheets/Forecasts?s=VAL:LSE

js8106455 - 26 Feb 2015 16:17 - 53 of 55

Listen: ValiRx - New endometriosis patent grant

click here

LGriffith - 14 May 2015 14:05 - 54 of 55

more news regarding ValiSeek: http://brrmedia.co.uk/event/138620/dr-suzanne-dilly-ceo-valiseek-limited

skyhigh - 25 May 2015 17:46 - 55 of 55

bought some last week at 39p,, so far so good!
  • Page:
  • 1
  • 2
  • 3
Register now or login to post to this thread.